References
- Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–342.
- Raza A, Sood GK. Hepatocellular carcinoma review: current treatment, and evidence-based medicine. World J Gastroenterol. 2014;20(15):4115–4127.
- Lammer J, Malagari K, Vogl T, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol. 2010;33(1):41–52.
- Lau WY. Management of hepatocellular carcinoma. J R Coll Surg Edinb. 2002;47(1):389–399.
- Yu SJ, Yoon JH, Lee JH, et al. Inhibition of hypoxia-inducible carbonic anhydrase-IX enhances hexokinase II inhibitor-induced hepatocellular carcinoma cell apoptosis. Acta Pharmacol Sin. 2011;32(7):912–920.
- Saito A, Toyoda H, Kobayashi M, et al. Prediction of early recurrence of hepatocellular carcinoma after resection using digital pathology images assessed by machine learning. Mod Pathol. 2021;34(2):417–425.
- Grazi GL, Ercolani G, Pierangeli F, et al. Improved results of liver resection for hepatocellular carcinoma on cirrhosis give the procedure added value. Ann Surg. 2001;234(1):71–78.
- Song KD, Lee MW, Rhim H, et al. Aggressive intrasegmental recurrence of hepatocellular carcinoma after combined transarterial chemoembolization and radiofrequency ablation. AJR Am J Roentgenol. 2016;207(5):1122–1127.
- Tezuka M, Hayashi K, Kubota K, et al. Growth rate of locally recurrent hepatocellular carcinoma after transcatheter arterial chemoembolization: comparing the growth rate of locally recurrent tumor with that of primary hepatocellular carcinoma. Dig Dis Sci. 2007;52(3):783–788.
- Kim JK, Kim HD, Jun MJ, et al. Tumor volume doubling time as a dynamic prognostic marker for patients with hepatocellular carcinoma. Dig Dis Sci. 2017;62(10):2923–2931.
- Weljie AM, Jirik FR. Hypoxia-induced metabolic shifts in cancer cells: moving beyond the warburg effect. Int J Biochem Cell Biol. 2011;43(7):981–989.
- Feron O. Pyruvate into lactate and back: from the Warburg effect to symbiotic energy fuel exchange in cancer cells. Radiother Oncol. 2009;92(3):329–333.
- Estrella V, Chen T, Lloyd M, et al. Acidity generated by the tumor microenvironment drives local invasion. Cancer Res. 2013;73(5):1524–1535.
- Colegio OR, Chu NQ, Szabo AL, et al. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature. 2014;513(7519):559–563.
- Gwak GY, Yoon JH, Kim KM, et al. Hypoxia stimulates proliferation of human hepatoma cells through the induction of hexokinase II expression. J Hepatol. 2005;42(3):358–364.
- Cho EJ, Yu SJ, Kim K, et al. Carbonic anhydrase-IX inhibition enhances the efficacy of hexokinase II inhibitor for hepatocellular carcinoma in a murine model. J Bioenerg Biomembr. 2019;51(2):121–129.
- Mboge MY, Mahon BP, McKenna R, et al. Carbonic anhydrases: role in pH control and cancer. Metabolites. 2018;8(1):19.
- Savic LJ, Doemel LA, Schobert IT, et al. Molecular MRI of the immuno-metabolic interplay in a rabbit liver tumor model: a biomarker for resistance mechanisms in tumor-targeted therapy? Radiology. 2020;296(3):575–583.
- Martínez-Zaguilán R, Seftor EA, Seftor RE, et al. Acidic pH enhances the invasive behavior of human melanoma cells. Clin Exp Metastasis. 1996;14(2):176–186.
- Supuran CT, Alterio V, Di Fiore A, et al. Inhibition of carbonic anhydrase IX targets primary tumors, metastases, and cancer stem cells: three for the price of one. Med Res Rev. 2018;38(6):1799–1836.